HIV and ID Observations

October 8th, 2018

“Mini”-Really Rapid Review — IDWeek 2018, San Francisco

Once upon a time, the annual meeting of the Infectious Diseases Society of America (IDSA) wasn’t much of a research conference. It consisted mostly of review sessions on topics deemed worthy of an update or a refresher, led by noted experts in the field. They would cite the latest literature on endocarditis, or mycoplasma, or prosthetic […]

---

September 9th, 2018

Doravirine Sets a New Standard for NNRTIs — But What Role in HIV Treatment Today?

The HIV drug class called “non-nucleoside reverse transcriptase inhibitors,” or NNRTIs, must have something of an inferiority complex. First, anything defined by what it is not is already in trouble. Believe me, hepatitis C was thrilled when it could shed the “non-A, non-B hepatitis” label. Second, despite their high antiviral potency and good tolerability, the NNRTIs have […]

---

August 23rd, 2018

Eye Worm, MALDI-TOF, New Lyme Testing Approach, Dogs Fail as C. diff Testers, Uiyk (?), and More — A Summer Is Getting Shorter ID Link-o-Rama

A recent chilly spell here in Boston recalled a universal truth about aging — that summer seems to get shorter every year. As far as I can tell in my unscientific poll of everyone who will engage with me on this topic, there are no exceptions to this rule. Everyone thinks summer is shorter than when […]

---

August 5th, 2018

Why Caring for People with HIV Is Still Great

Earlier this year, I wrote a piece about friends and colleagues of mine who have left HIV clinical practice. Something about it touched a nerve. It’s one of the most commented-on pieces in the history of this blog. Read this for a typical response. Admittedly, it was kind of a downer — but it might have been […]

---

July 22nd, 2018

FDA Approves First PI-Based Single-Tablet Treatment for HIV — How Will It Be Used?

The latest HIV drug approval from the FDA came this past week with the release of a single-tablet treatment containing the following drugs: Darunavir (DRV) 800 mg Cobicistat (c) 150 mg Emtricitabine (FTC) 200 mg Tenofovir alafenamide (TAF) 10 mg Often abbreviated “DCF-TAF,” this is the first full treatment regimen in a single pill with a […]

---

July 15th, 2018

On-Service Digest, July 2018 — with Special Section Just for Staph aureus

I’m currently on-service for the inpatient ID consult team, and this is July. At a teaching hospital.  Here’s where some would play scary music. After all, the interns and fellows have just started! YIKES! But no scary music for me — I love working with the July newbies. Because whatever they lack in experience or efficiency, they more than make up […]

---

July 8th, 2018

Surgeon Who Was Denied Disability Insurance for Taking PrEP Tells His Story

Earlier this year, urology resident Dr. Philip Cheng appeared on the front page of the New York Times. Here was the headline: He Took a Drug to Prevent AIDS. Then He Couldn’t Get Disability Insurance. The piece understandably drew widespread attention, with sharp disapproval of the denial from ID specialists and public health officials. We couldn’t […]

---

May 28th, 2018

Predatory Journals Are Such a Big Problem It’s Not Even Funny

I’ve made fun of academic spam numerous times on this site. It’s those emails from dubious “predatory journals,” written in cheerful but awkward prose, with flowery praise and open invitations to submit research on various scientific topics. You know, the emails that start: Dear Dr. Paul E. Greetings for the day! Most of my coverage has been on […]

---

May 20th, 2018

Why the Dolutegravir Pregnancy Warning Is Important — and What We Should Do Now

Last week, in response to newly available surveillance data, multiple agencies issued a warning about the HIV integrase inhibitor dolutegravir (DTG) and pregnancy. The warnings cite an increased risk of neural tube defects in babies born to women who became pregnant while receiving the drug. From the U.S. Department of Health and Human Services: The concern stems from […]

---

May 6th, 2018

Looking Back on a Decade of Blogging About HIV and Infectious Diseases

Last week, Dr. Wendy Armstrong from Emory kindly invited me to spend some time with their smart, energetic ID fellows. (See if you can pick me out of the group in the photo at right — hint, I’m the old guy on the left.) Before the trip, Wendy asked them whether they’d rather hear me give a […]

---